1Kaminski M S,Tuck M,Estes J,et al.131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma[].The New England Journal of Medicine.2005 被引量：1
2Conconi A,Martinelli G,Thieblemont C,et al.Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type[].Blood.2003 被引量：1
3Gopal AK,Gooley TA,Maloney DG,et al.High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma[].Blood.2003 被引量：1
4Cheson BD.Radioimmunotherapy of non-Hodgkin lymphomas[].Current Drug Targets.2006 被引量：1
5Marcus R,Imrie K,Belch A,et al.CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma[].Blood.2005 被引量：1
6Hiddemann W,Kneba M,Dreyling M,et al.Frontline therapy with rituximab addedto the combination of cyclophosphamide,doxorubicin,vincrestine,and prednisone(CHOP)significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone[].Blood.2005 被引量：1
7Gheilmini M,Schimitz SF,Cogliatti SB,et al.Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x4schedule[].Blood.2004 被引量：1
8Czuczman MS,Weaver R,Alkuzweny B,et al.Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy:9-year follow-up[].Journal of Clinical Oncology.2004 被引量：1
9Witzig TE,Flinn IW,Gordon LI,et al.Treatment.with ibritumomab tiuxetan radioimmunotherapy inpatients with rituximab-refractory follicular non-Hodgkin’s lymphoma[].Journal of Clinical Oncology.2002 被引量：1
10Lenz G,Dreyling M,Hoster E,et al.Immunochemotherapy with rituximab and cyclophosphamide,doxorubicin,vincristine,and prednisone significantly improves response and time to treatment failure,but not long-term outcome in patients with previously untreated mantle cell lymphoma[].Journal of Clinical Oncology.2005 被引量：1
6Bianco R,Melisi D,Ciardiello F,et aI.Key cancer cell signal transduction pathways as therapeutic targets[J]. Eur J Cancer,2006,42(3):290-294,. 被引量：1
7Wong SF.Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment ofcolorectal cancer [J]. Clin Ther,2005,27(6):684-694. 被引量：1
8Kalofonos HP,Grivas PD.Monoclonal antibodies in the management of solid tumors[J]. Curr Top Med Chem,2006,6(16):1687-1705. 被引量：1
